InnoCan Pharma's Defining Moment: A Shareholder Vote That Could Settle the US Listing Question

InnoCan Pharma faces pivotal shareholder vote on rebrand to Velsa Corp. amid prolonged US listing, insider bridge loans, and strong wellness growth.

When InnoCan Pharma shareholders gather on August 17, 2026, they will be voting on more than just a new corporate identity. The outcome of that meeting — including the proposed rebrand to Velsa Corp. — may well determine whether the company can finally close the chapter on a US listing process that has stretched across multiple SEC filings since 2025.

The Waiting Game and Its Costs

The company's path to a US exchange has been anything but smooth. InnoCan has applied to list its common shares and warrants under the tickers "INNP" and "INNPW," with ThinkEquity serving as underwriter. The F-1 registration statement filed with the SEC has undergone several rounds of amendments, and neither an offering price nor a completion date has been set.

That prolonged timeline forced the company to seek bridge financing from its largest shareholder. In March, InnoCan closed a $450,000 loan with Tamar Innovest Limited, followed by a second, non-convertible tranche of $200,000 from the same lender in April. Both carry a 10 percent annual interest rate and mature either twelve months from issuance or upon completion of the US listing — whichever comes first. The fact that two separate insider rounds were needed within weeks of each other suggests the company couldn't secure broader external funding to ease its short-term liquidity pressure.

Two Businesses, Two Stories

The most recent quarterly report, covering the three months ending March 31, 2026, illustrates the company's dual-engine model. Consolidated revenue reached $6.465 million, a sequential improvement of 29.7 percent. But against the same period a year earlier, when revenue stood at $7.796 million, that represents a decline of 17.07 percent. Management attributed the quarter-over-quarter gains to cost reductions and improved gross margins in the wellness segment, which helped contain net losses.

The consumer wellness arm, operating through the BI Sky Global Ltd. joint venture in which InnoCan holds a 60 percent stake, has been the bright spot. On August 5, the company announced that its skincare brand Valitic had surpassed 100,000 verified positive customer reviews on major US marketplaces — just days after crossing the two-million-customer mark in late July. The strategy is straightforward: cash flow from the high-margin wellness business funds the pharmaceutical pipeline, anchored by the LPT-CBD liposome platform being developed for pain management and epilepsy indications.

Regulatory Progress on the Veterinary Front

While the consumer business hits milestones, the clinical side has made quieter but meaningful advances. The FDA's veterinary medicine division has assigned an INAD number to the LPT-CBD platform, a formal prerequisite for advancing new animal drug approvals in the US. The agency has also waived the sponsor fee for 2026 — the third consecutive year InnoCan has received this regulatory support for its veterinary applications.

A Week of Volatility

The market's mood has been mixed. At the Hamburg exchange, InnoCan shares closed Friday, August 7, at €1.500, up 1.69 percent from the prior session's €1.475 close. That friendly finish belied a choppy week in which the stock at times fell as much as 9 percent intraday. Those swings reflect a broader investor debate: can InnoCan sustainably fund its pharma pipeline from its own operations, or will it remain dependent on insider financing?

What August 17 Will Tell Investors

Shareholders voting by proxy must submit their ballots by August 13 at 10:00 a.m. Eastern Time. Only those registered in the company's share register as of July 13 are eligible to vote.

A smooth vote that clears the structural hurdles — including the Velsa Corp. rebrand — would signal continuity on the road to the US listing, potentially allowing the company to complete the offering on firmer footing, financed by its own wellness business rather than additional insider loans. A contentious or postponed vote, by contrast, would prolong the uncertainty, keeping the company reliant on related-party debt and raising the prospect of further dilutive capital raises before any Nasdaq or NYSE American listing materializes.

The immediate roadmap is clear: the August 17 shareholder meeting, followed by any update to the F-1 registration status with the SEC. For a company that has spent over a year navigating regulatory review, the next few weeks will determine whether the path forward leads to a listing — or another round of waiting.